Daily Stock Analysis, APEN, Apollo Endosurgery Inc, priceseries

Apollo Endosurgery Inc. Daily Stock Analysis
Stock Information
Open
2.80
Close
2.90
High
2.90
Low
2.80
Previous Close
2.86
Daily Price Gain
0.04
YTD High
4.10
YTD High Date
Feb 11, 2019
YTD Low
2.52
YTD Low Date
Aug 7, 2019
YTD Price Change
-0.75
YTD Gain
-20.55%
52 Week High
5.20
52 Week High Date
Dec 3, 2018
52 Week Low
2.52
52 Week Low Date
Aug 7, 2019
52 Week Price Change
-1.05
52 Week Gain
-26.58%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 11. 2017
6.86
May 12. 2017
7.76
1 Trading Days
13.05%
Link
LONG
Jul 24. 2017
6.75
Jul 27. 2017
7.11
3 Trading Days
5.33%
Link
LONG
Sep 29. 2017
4.68
Oct 13. 2017
5.23
10 Trading Days
11.69%
Link
LONG
Dec 19. 2017
4.25
Jan 17. 2018
5.95
18 Trading Days
40.05%
Link
Company Information
Stock Symbol
APEN
Exchange
NasdaqGM
Company URL
http://www.apolloendo.com
Company Phone
512-279-5100
CEO
Todd Newton
Headquarters
Texas
Business Address
1120 SOUTH CAPITAL OF, TX HWY, BUILDING 1 SUITE 300, AUSTIN, TX 78746
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001251769
About

Apollo Endosurgery, Inc. develops medical devices. It offers medical devices for bariatric and gastrointestinal procedures. The firm's brands include Orbera, Lap-band SYSTEM and OverStitch. The company was founded by Christopher J. Gostout in 2006 and is headquartered in Austin, TX.

Description

Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States. It develops Lpathomab, a humanized monoclonal antibody (mAb) against lysophosphatidic acid that has completed Phase 1a clinical trial for various chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. The company also develops iSONEP, a mAb against sphingosine-1-phosphate, which is in Phase II clinical trial for the treatment of wet age-related macular degeneration; and ASONEP, a systemic formulation of sonepcizumab and a mAb against the bioactive lipid sphingosine-1-phosphate (S1P), which is in Phase IIa clinical trial to treat kidney cancer, leukemia, prostate cancer, neuroblastoma, lung cancer, pancreatic cancer, and melanoma. Lpath, Inc. has a collaboration agreement with Pfizer Inc. to develop and commercialize iSONEP. Lpath, Inc. is based in San Diego, California.